#USA #Tokyo #ADC technology #Ajinomoto #Bio-Pharma

Ajinomoto Bio-Pharma Services Shines at the World ADC Awards

Ajinomoto Bio-Pharma Services, known as Aji Bio-Pharma, has made a notable impact by winning the "Best ADC Preclinical Publication 2024" award at the prestigious 2025 World ADC Awards. This recognition is a testament to the company's unwavering commitment to innovation and excellence in the biopharmaceutical sector, particularly in the development of antibody-drug conjugates (ADCs).

The award was presented for the research publication titled "Exo-Cleavable Linkers Enhanced Stability and Therapeutic Efficacy in Antibody–Drug Conjugates," which appeared in the Journal of Medicinal Chemistry. This significant work details the design, synthesis, preparation, and biological evaluation of the AJICAP® linker technology, showcasing how it enhances the performance of ADCs. The study highlights the company's innovative approach to developing stable and efficient linker systems that are essential for creating next-generation ADC therapies.

In a statement following the award announcement, Yasuyuki Otake, the Corporate Executive and General Manager of the Bio-Pharma Services Department at Ajinomoto Co., Inc., expressed gratitude for the acknowledgment from the World ADC community. He emphasized that the AJICAP® technology embodies the company's dedication to empowering collaborators in delivering breakthrough ADC therapies to the patients who need them most.

The World ADC Awards, organized by Hanson Wade, honor achievements in scientific and operational excellence related to the discovery, development, and manufacturing of ADCs. Aji Bio-Pharma had previously been shortlisted in the "Best ADC Platform Technology" category, demonstrating the high regard in which their technology is held within the biopharmaceutical industry. The winners of these awards are chosen by an independent panel composed of experts in the field, further underscoring the significance of this recognition.

This accolade marks another milestone in Aji Bio-Pharma's ongoing journey of innovation within the ADC technology domain. The company is steadfast in its mission to develop safer and more effective therapeutic options for patients worldwide, advancing the biopharmaceutical industry at large.

About Ajinomoto Bio-Pharma Services

Ajinomoto Bio-Pharma Services is a fully integrated contract development and manufacturing organization with operations in Belgium, India, Japan, and the United States. They specialize in supporting a broad spectrum of services, ranging from gene therapy and Active Pharmaceutical Ingredients (APIs) to the manufacturing of both large and small molecules. Their innovative capabilities span pre-clinical to commercial scale production, including high potency APIs (HPAPI), continuous flow manufacturing, and oligonucleotide synthesis, among others.

Committed to providing top-notch quality and service, Aji Bio-Pharma continues to meet the evolving needs of its clients while pushing the boundaries of biopharmaceutical development. For further information about their services and technology, visit www.AjiBio-Pharma.com.